MA53287A - Inhibiteurs de prmt5 - Google Patents
Inhibiteurs de prmt5Info
- Publication number
- MA53287A MA53287A MA053287A MA53287A MA53287A MA 53287 A MA53287 A MA 53287A MA 053287 A MA053287 A MA 053287A MA 53287 A MA53287 A MA 53287A MA 53287 A MA53287 A MA 53287A
- Authority
- MA
- Morocco
- Prior art keywords
- prmt5 inhibitors
- prmt5
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862715446P | 2018-08-07 | 2018-08-07 | |
US201962792623P | 2019-01-15 | 2019-01-15 | |
US201962859490P | 2019-06-10 | 2019-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53287A true MA53287A (fr) | 2022-05-11 |
Family
ID=69414248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053287A MA53287A (fr) | 2018-08-07 | 2019-08-05 | Inhibiteurs de prmt5 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220363707A1 (fr) |
EP (1) | EP3833355A4 (fr) |
JP (1) | JP7446282B2 (fr) |
KR (1) | KR20210046009A (fr) |
CN (1) | CN112805006A (fr) |
AU (1) | AU2019317549A1 (fr) |
BR (1) | BR112021002267A8 (fr) |
CA (1) | CA3108388A1 (fr) |
MA (1) | MA53287A (fr) |
MX (1) | MX2021001486A (fr) |
WO (1) | WO2020033288A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020081257A1 (fr) | 2018-10-05 | 2020-04-23 | Vertex Pharmaceuticals Incorporated | Modulateurs de l'alpha -1 antitrypsine |
US11198699B2 (en) | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
UY38696A (es) | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
CN114126614A (zh) * | 2019-05-30 | 2022-03-01 | 安杰斯制药公司 | 作为prmt5抑制剂的杂环化合物 |
EP4069698A1 (fr) | 2019-12-03 | 2022-10-12 | Lupin Limited | Analogues nucléosidiques substitués en tant qu'inhibiteurs de prmt5 |
US20220112194A1 (en) * | 2020-04-01 | 2022-04-14 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
CN115697969A (zh) * | 2020-04-03 | 2023-02-03 | 弗特克斯药品有限公司 | 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的7-或8-羟基-异喹啉和7-或8-羟基-喹啉衍生物 |
WO2023001133A1 (fr) * | 2021-07-20 | 2023-01-26 | 上海齐鲁制药研究中心有限公司 | Inhibiteur de prmt5 |
WO2023017152A1 (fr) | 2021-08-13 | 2023-02-16 | Albert-Ludwigs-Universität Freiburg | Inhibiteurs à petites molécules spécifiques qui bloquent l'activité et la fonction de la méthyltransférase kmt9 |
CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
TW202406908A (zh) * | 2022-08-09 | 2024-02-16 | 大陸商上海湃隆生物科技有限公司 | 新型prmt5抑制劑及其應用 |
WO2024101965A1 (fr) * | 2022-11-10 | 2024-05-16 | 에스케이바이오팜 주식회사 | Combinaison pharmaceutique d'inhibiteur de prmt5 et de substance induisant des dommages à l'adn |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5721275B2 (ja) * | 2009-04-22 | 2015-05-20 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール, ブイ.ブイ.アイ. | 治療的使用のための新規7−デアザプリンヌクレオシド |
WO2012170347A1 (fr) * | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Nucléosides bicycliques et composés oligomères préparés à partir de ceux-ci |
US20170198006A1 (en) * | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
TW202321249A (zh) * | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
CN105837573B (zh) * | 2016-03-28 | 2018-07-27 | 江西青峰药业有限公司 | 一种9-[3a,6-二羟基六氢-1H-环戊二烯并[c]呋喃-4-基]鸟嘌呤的制备方法 |
WO2018065365A1 (fr) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 |
MX2020001598A (es) | 2017-08-09 | 2020-10-28 | Prelude Therapeutics Inc | Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5). |
-
2019
- 2019-08-05 WO PCT/US2019/045050 patent/WO2020033288A1/fr unknown
- 2019-08-05 MX MX2021001486A patent/MX2021001486A/es unknown
- 2019-08-05 CA CA3108388A patent/CA3108388A1/fr active Pending
- 2019-08-05 EP EP19846885.2A patent/EP3833355A4/fr active Pending
- 2019-08-05 BR BR112021002267A patent/BR112021002267A8/pt unknown
- 2019-08-05 JP JP2021506583A patent/JP7446282B2/ja active Active
- 2019-08-05 US US17/266,521 patent/US20220363707A1/en active Pending
- 2019-08-05 AU AU2019317549A patent/AU2019317549A1/en active Pending
- 2019-08-05 MA MA053287A patent/MA53287A/fr unknown
- 2019-08-05 KR KR1020217006756A patent/KR20210046009A/ko active Search and Examination
- 2019-08-05 CN CN201980065660.9A patent/CN112805006A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020033288A1 (fr) | 2020-02-13 |
CA3108388A1 (fr) | 2020-02-13 |
JP2022501316A (ja) | 2022-01-06 |
US20220363707A1 (en) | 2022-11-17 |
EP3833355A4 (fr) | 2022-05-11 |
CN112805006A (zh) | 2021-05-14 |
JP7446282B2 (ja) | 2024-03-08 |
AU2019317549A1 (en) | 2021-02-25 |
EP3833355A1 (fr) | 2021-06-16 |
BR112021002267A8 (pt) | 2023-02-07 |
MX2021001486A (es) | 2021-07-15 |
KR20210046009A (ko) | 2021-04-27 |
BR112021002267A2 (pt) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54543A (fr) | Inhibiteurs de kif18a | |
MA54550A (fr) | Inhibiteurs de kif18a | |
MA53287A (fr) | Inhibiteurs de prmt5 | |
MA52413A (fr) | Inhibiteurs de cd73 | |
MA52812A (fr) | Inhibiteurs de sarm1 | |
DK3704120T3 (da) | Heterocykliske forbindelser som prmt5-inhibitorer | |
MA52635A (fr) | Inhibiteurs de magl | |
DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
DK3571192T3 (da) | Jak1-selektive inhibitorer | |
DK3746446T3 (da) | PRC2-inhibitorer | |
MA55909A (fr) | Inhibiteurs de cdk | |
DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
MA52809A (fr) | Inhibiteurs de sarm1 | |
MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
MA52813A (fr) | Inhibiteurs de sarm1 | |
DK3710457T3 (da) | Immunproteasomhæmmere | |
DK3720840T3 (da) | Cathepsinhæmmere | |
DK3752258T3 (da) | Trampolin | |
DK3587968T3 (da) | Fluidsystem | |
MA49925A (fr) | Claie | |
DE112019000442A5 (de) | Ringtilgereinrichtung | |
NO20181678A1 (no) | Rissanviser | |
JP1628555S (ja) | たい焼 | |
JP1628556S (ja) | たい焼 |